Expertise in
13
conditions

Dr. Tawee Tanvetyanon

Oncology
Moffitt Cancer Center At International Plaza
4101 Jim Walter Blvd, 
Tampa, FL 
Accepting New Patients
Offers Telehealth
Expertise in
13
conditions
Moffitt Cancer Center At International Plaza
4101 Jim Walter Blvd, 
Tampa, FL 

Overview

Tawee Tanvetyanon is an Oncologist practicing medicine in Tampa, Florida.

Dr. Tanvetyanon is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Small Cell Lung Cancer (SCLC), and Thymectomy.

He is actively involved in clinical research, co-authoring 105 peer reviewed articles and participating in 16 clinical trials. Dr. Tanvetyanon is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Florida Blue
  • EPO
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Moffitt Cancer Center at International Plaza
4101 Jim Walter Blvd, Tampa, FL 33607
Other Locations
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma
A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma
Enrollment Status: Completed
Publish Date: April 21, 2026
Intervention Type: Biological, Drug
Study Drugs: rAd-IFN, Celecoxib, Gemcitabine
Study Phase: Phase 3
Sequential Maintenance With Thoracic Radiotherapy and Durvalumab (MEDI4736) Monotherapy or Durvalumab (MEDI 4736) Combinations (Tremelimumab or Olaparib) in Patients With Extensive Stage-Small Cell Lung Cancer After First Line Platinum Based Chemotherapy
Sequential Maintenance With Thoracic Radiotherapy and Durvalumab (MEDI4736) Monotherapy or Durvalumab (MEDI 4736) Combinations (Tremelimumab or Olaparib) in Patients With Extensive Stage-Small Cell Lung Cancer After First Line Platinum Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 01, 2026
Intervention Type: Drug, Radiation
Study Drugs: Durvalumab, Tremelimumab, Olaparib
Study Phase: Phase 1
A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 19, 2026
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, AZD1775
Study Phase: Phase 2
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Enrollment Status: Completed
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 3
A Phase I/II Study of Pembrolizumab and Vorinostat in Patients With Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC
A Phase I/II Study of Pembrolizumab and Vorinostat in Patients With Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2025
Intervention Type: Drug
Study Drugs: Vorinostat, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Transarterial Chemoperfusion Treatment With Cisplatin, Methotrexate and Gemcitabine in Patients With Unresectable Pleural Mesothelioma
A Phase 2 Study of Transarterial Chemoperfusion Treatment With Cisplatin, Methotrexate and Gemcitabine in Patients With Unresectable Pleural Mesothelioma
Enrollment Status: Completed
Publish Date: December 18, 2025
Intervention Type: Drug, Other
Study Drugs: Cisplatin, Methotrexate, Gemcitabine
Study Phase: Phase 2
A Phase I/Ib Trial of Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
A Phase I/Ib Trial of Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Enrollment Status: Completed
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drugs: Pirfenidone, Carboplatin, Paclitaxel, Pemetrexed
Study Phase: Phase 1
A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Enrollment Status: Completed
Publish Date: October 30, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Paclitaxel, Ramucirumab
Study Phase: Phase 2
Consolidative Ipilimumab and Nivolumab With Thoracic Radiotherapy After Platinum Based Chemotherapy for Patients With Extensive-Stage Small Cell Lung Cancer
Consolidative Ipilimumab and Nivolumab With Thoracic Radiotherapy After Platinum Based Chemotherapy for Patients With Extensive-Stage Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Radiation, Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
Activity and Enhancement of Immune Checkpoint Inhibition With Lurbinectedin in Relapsed/Recurrent Small Cell Lung Cancer (SCLC)
Activity and Enhancement of Immune Checkpoint Inhibition With Lurbinectedin in Relapsed/Recurrent Small Cell Lung Cancer (SCLC)
Enrollment Status: Terminated
Publish Date: April 02, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab, Lurbinectedin
Study Phase: Phase 1
View 9 Less Clinical Trials

105 Total Publications

Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.
Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: August 17, 2026
Similar Doctors
Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (8.7 miles away)
813-934-6811
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Philippe Spiess is an Oncologist practicing medicine in Tampa, Florida. Dr. Spiess is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Penile Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Penectomy. Dr. Spiess is currently accepting new patients.

Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (8.7 miles away)
813-692-4147
Languages Spoken:
English, Czech, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Lubomir Sokol is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Sokol is highly rated in 55 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sokol is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (8.7 miles away)
813-934-6809
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Wade Sexton is an Oncologist practicing medicine in Tampa, Florida. Dr. Sexton is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Orchiectomy. Dr. Sexton is currently accepting new patients.

Frequently Asked Questions about Dr. Tawee Tanvetyanon

How do I make an appointment with Dr. Tawee Tanvetyanon?

You can book an appointment with Dr. Tawee Tanvetyanon by calling their office at 813-566-0883. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tawee Tanvetyanon a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tawee Tanvetyanon is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tawee Tanvetyanon specialize in?

While Dr. Tawee Tanvetyanon is a Oncology, they have specific expertise in Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Mesothelioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Tawee Tanvetyanon participate in research or clinical trials?

Yes. Dr. Tawee Tanvetyanon has published 105 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Tawee Tanvetyanon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Tawee Tanvetyanon accept my insurance?

Dr. Tawee Tanvetyanon accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 813-566-0883 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tanvetyanon's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile